Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydronidone capsules safety in chronic hepatitis B liver fibrosis
CTR20260486Phase 2Completed
- Sponsor
- Gyre Pharmaceuticals
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of hydronidone in Chronic Hepatitis B (CHB), hepatic fibrosis, sponsored by Gyre Pharmaceuticals. Started Apr 2026; status: completed.
02
Drugs
hydronidone
03
Conditions
Chronic Hepatitis B (CHB)hepatic fibrosis
Beyond the preview
Go deeper on CTR20260486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260486.